Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) insider John Militello sold 833 shares of the stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $22.87, for a total value of $19,050.71. Following the completion of the transaction, the insider now owns 54,406 shares of the company’s stock, valued at approximately $1,244,265.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
John Militello also recently made the following trade(s):
- On Thursday, March 21st, John Militello sold 2,490 shares of Rocket Pharmaceuticals stock. The shares were sold at an average price of $28.10, for a total transaction of $69,969.00.
- On Thursday, February 29th, John Militello sold 10,000 shares of Rocket Pharmaceuticals stock. The stock was sold at an average price of $29.84, for a total transaction of $298,400.00.
Rocket Pharmaceuticals Stock Down 0.5 %
RCKT opened at $21.98 on Friday. The company has a market capitalization of $1.99 billion, a PE ratio of -7.48 and a beta of 1.07. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.80 and a quick ratio of 7.80. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $14.89 and a fifty-two week high of $32.53. The business has a 50-day moving average of $26.70 and a 200-day moving average of $25.41.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its position in Rocket Pharmaceuticals by 56.0% during the third quarter. Wellington Management Group LLP now owns 8,022,830 shares of the biotechnology company’s stock worth $164,388,000 after buying an additional 2,880,373 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Rocket Pharmaceuticals by 18.3% during the 4th quarter. Vanguard Group Inc. now owns 5,447,565 shares of the biotechnology company’s stock worth $163,264,000 after acquiring an additional 843,552 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Rocket Pharmaceuticals by 14.7% during the 3rd quarter. Westfield Capital Management Co. LP now owns 4,193,996 shares of the biotechnology company’s stock worth $85,935,000 after acquiring an additional 538,209 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Rocket Pharmaceuticals by 105.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 877,140 shares of the biotechnology company’s stock valued at $17,973,000 after acquiring an additional 449,569 shares during the last quarter. Finally, Comerica Bank bought a new position in shares of Rocket Pharmaceuticals in the 3rd quarter valued at approximately $9,017,000. Institutional investors own 98.39% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently commented on RCKT shares. UBS Group decreased their price objective on shares of Rocket Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, March 1st. StockNews.com raised Rocket Pharmaceuticals to a “sell” rating in a research report on Friday, February 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 price target on shares of Rocket Pharmaceuticals in a research report on Tuesday, February 27th. The Goldman Sachs Group began coverage on Rocket Pharmaceuticals in a research note on Tuesday, April 2nd. They issued a “neutral” rating and a $39.00 price objective for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $53.00 target price on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $52.13.
View Our Latest Research Report on RCKT
Rocket Pharmaceuticals Company Profile
Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.
Further Reading
- Five stocks we like better than Rocket Pharmaceuticals
- Buy P&G Now, Before It Sets A New All-Time High
- 3 Stocks Leading the U.S. Agriculture Comeback
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Retail Stocks Investing, Explained
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.